BTIG Research started coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note published on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $35.00 price objective on the stock.

YMAB stock opened at $21.50 on Tuesday. Y-mAbs Therapeutics has a 1 year low of $18.00 and a 1 year high of $31.00.

In other Y-mAbs Therapeutics news, Director James Healy acquired 500,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, September 21st. The stock was acquired at an average price of $16.00 per share, with a total value of $8,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ashu Tyagi acquired 430,174 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Tuesday, September 25th. The stock was acquired at an average cost of $16.00 per share, with a total value of $6,882,784.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 961,424 shares of company stock valued at $15,382,784.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: Should You Consider an Index Fund?

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.